been recently recognized — the company
was named one of Deloitte’s Technology
Fast50™ Companies last year. Gillis attri-
butes this success to the company’s ability
to fill a unique market exigency — a peti-
tion for patient choice. “It’s supply and de-
mand and the demand is certainly there,”
Gillis said. When patients and physicians
need access to medication but face inter-
rupted or non-existent coverage, that ne-
cessitates the involvement of an interme-
diary party in the marketplace.
As the years have gone by, awareness
of STI’s programs has increased and this
recognition has contributed to the com-
pany’s growth as well. Technology and so-
cial media have allowed for this awareness
to proliferate, but simply getting the word
out through conventional patient-to-doctor
conversations has also helped.
Increased awareness also contributes to
the challenges of operating a company
involved with pharma and financial cover-
age. “The toughest challenge is miscon-
ceptions by stakeholders whether that
be government or pharmacy. Health care,
in general, is a very complex ecosystem
with many moving parts and competing
interests, so we’ve had to expend energy
dispelling any uncertainty or fear about the
“Per patient cost for therapy is getting higher and higher. The good news is there
is innovation in medicine. The bad news is it’s expensive.”
Dave Morton, EVP Sales
and Marketing
JUNE 2016
H
business elite canada
7
